These 2 Under-The-Radar Biotechs Are Potential Multibaggers

With approximately 100 new biotech companies having begun trading on the Nasdaq exchange since the beginning of last year alone, the author of today’s article observes that “There are so many new biotech stocks hitting the market that plenty of gems slip through the cracks unnoticed” – and he goes on to highlight two of them. For these two under-the-radar biotechs – one of which has developed a potential new treatment for depression while the other “is taking advantage of gravity to develop a blindness prevention drug that lasts longer than the competition” – CLICK HERE.